Drug Trial Radar · NCT05462717
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
Last checked: Nov 20, 2026Latest source record: May 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
222
Planned (sponsor's estimate)
Start
Sep 19, 2022
Primary completion
Mar 31, 2027
Study completion Sep 30, 2027
Sponsor
- Lead sponsor
- Revolution Medicines, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 18, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of escalating doses of RMC-6291 (KRAS G12C(ON) inhibitor) monotherapy in adult subjects with advanced solid tumors and to identify the maximum tolerated dose (MTD), and the recommended Phase 2 dose.
Conditions
- Non-Small Cell Lung Cancer (NSCLC)
- Colorectal Cancer (CRC)
- Pancreatic Ductal Adenocarcinoma
- Advanced Solid Tumor
Interventions
RMC-6291Drug
Oral tablet once or twice a day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse eventsTime frame: up to 3 years
- Dose Limiting ToxicitiesTime frame: The first 21 days (i.e. Cycle 1)
Locations
64 sites in 13 countries. Site status is shown where the registry gives one.
Highlands Oncology Group
Springdale, Arkansas
UC Irvine Cancer Center
Orange, California
UC Davis Cancer Center
Sacramento, California
UCSF
San Francisco, California
University of Miami School of Medicine Sylvester Comprehensive Cancer Center
Miami, Florida
Moffitt Cancer Center
Tampa, Florida
American Oncology Partners of Maryland
Bethesda, Maryland
Dana-Farber Cancer Institute
Boston, Massachusetts
Roswell Park Comprehensive Cancer Center
Buffalo, New York
MSK Cancer Center
New York, New York
Columbia University Irving Medical Center
New York, New York
Tennessee Oncology
Nashville, Tennessee
Next Oncology
San Antonio, Texas
START
San Antonio, Texas
Next Oncology Virginia
Fairfax, Virginia
Southside Cancer Care Centre
Sydney, New South Wales, Australia
Peninsula & South Eastern Haematology and Oncology Group
Frankston, Victoria, Australia
Austin Health, Olivia Newton-John Cancer Research & Wellness Centre
Heidelberg, Victoria, Australia
South West Health Care
Warrnambool, Victoria, Australia
NH Hospital a.s.
Hořovice, Czechia
Klinika onkologie a radioterapie, Fakultni Nemocnice Hradec Kralove
Hradec Králové, Czechia
Onkologicka klinika, Fakultni Nemocnice Olomouc
Olomouc, Czechia
ICO
Angers, France
CHU Bordeaux Hospital Saint-Andre
Bordeaux, France
Centre Jean Perrin
Clermont-Ferrand, France
Centre Oscar Lambret
Lille, France
Centre Léon Bérard
Lyon, France
CHU Nantes
Nantes, France
ICANS
Strasbourg, France
S.C. Oncologia Falck, Dipartimento Ematologia ed Oncologia Niguarda Cancer Center
Milan, Italy
Istituto Europeo Oncologico
Milan, Italy
Istituto Nazionale Tumori Fondazione G. Pascale
Naples, Italy
Azienda Ospedaliero-Universitaria San Luigi Gonzaga
Orbassano, Italy
Fondazione IRCCS Policlinico San Matteo
Pavia, Italy
Centro Ricerche Cliniche di Verona s.r.l.
Verona, Italy
University Malaya Medical Centre
Kuala Lumpur, Malaysia
Sarawak General Hospital
Kuching, Malaysia
Instytut MSF Sp zoo
Lodz, Poland
Med - Polonia Sp. z o. o.
Poznan, Poland
Narodowy Instytut Onkologii
Warsaw, Poland
Showing 40 of 64 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.